Baxter International Inc (BAX) Stock Analysis and Metrics

Baxter International

NYSE: BAX

$22.40 ▲ +0.73 (+3.35%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap11.56 Bn

P/E-98.80

P/S1.07

Div. Yield0.02

ROIC (Qtr)1.38

Total Debt (Qtr)8.62 Bn

Revenue Growth (1y) (Qtr)2.90

Add ratio to table…

About

Baxter International Inc. provides a broad portfolio of essential healthcare products, including sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, advanced surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. These products serve hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision.

The company generates revenue primarily through the sale of its healthcare products and related services to healthcare providers and patients. Revenue is derived from the sale of sterile IV solutions, infusion sets, parenteral nutrition, inhaled anesthetics, injectable drugs, surgical sealants, smart beds, monitors, respiratory devices, and drug compounding services. Baxter sells its offerings via a direct sales force and through independent distributors, drug wholesalers, and specialty pharmacy providers in over 100 countries.

The company operates through the following segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

• Medical Products & Therapies: This segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies, and surgical hemostat, sealant, and adhesion prevention products.

• Healthcare Systems & Technologies: This segment includes sales of connected care solutions and collaboration tools, such as smart bed systems, patient monitoring systems, diagnostic technologies, respiratory health devices, and advanced surgical equipment including operating room integration technologies and precision positioning devices.

• Pharmaceuticals: This segment includes sales of specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services.

Baxter holds a strong position in the global healthcare industry due to its broad and deep product portfolio and extensive international footprint. The company benefits from competitive advantages such as wide-ranging offerings, strong relationships with hospitals and group purchasing organizations, shared manufacturing efficiencies, and technological innovation. While no single competitor matches Baxter across all its businesses, it faces substantial competition in each segment from diverse domestic and international healthcare, medical device, and pharmaceutical firms.

Baxter serves a diverse customer base that includes hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, physicians’ offices, kidney dialysis centers, and patients receiving care at home under physician supervision.

Investment Thesis

▲ Bull case

Baxter's strategic focus on innovation and AI integration presents a significant growth opportunity. The company's recent launches, such as the IV Verified Line labeling system and the XR spine surgical table, demonstrate a commitment to targeted innovation. Additionally, the integration of AI into the Connected Care Foundation and frontline care products aims to accelerate future growth. These initiatives position Baxter to outgrow its markets and expand margins, leveraging its unique data set from IoT devices to provide actionable insights. The company's proactive approach to innovation, coupled with strong order growth for products like Dynamo, suggests a robust pipeline of differentiated solutions that could drive long-term shareholder value.
The company's efforts to stabilize the business and strengthen the balance sheet are showing early signs of success. Baxter's positive free cash flow generation in Q1 FY26 reflects progress in improving working capital efficiency. The company's target of net leverage of approximately 3x by the end of FY26 indicates a disciplined approach to debt reduction and financial flexibility. Once this leverage goal is achieved, Baxter will have more optionality for strategic tuck-in M&A and share repurchases, enhancing its growth profile and shareholder returns. The company's focus on continuous improvement through the Baxter Growth and Performance System (GPS) is expected to drive accountability and operational efficiency, further strengthening its financial position.
Baxter's exposure to macroeconomic risks, such as higher oil prices and conflict in the Middle East, is relatively low. With less than 2% of total revenue coming from the Middle East and significantly reduced exposure to fuel costs post-divestiture of the kidney business, Baxter is well-positioned to navigate broader economic uncertainties. The company's proactive supply chain management and dual sourcing efforts mitigate risks associated with inflation and supply chain disruptions. Baxter's ability to manage these risks while maintaining operational resilience underscores its potential for consistent performance and long-term growth.
The company's strategic priorities, including stabilizing the business, strengthening the balance sheet, and driving continuous improvement, are gaining traction. Baxter's progress in clearing back orders and increasing throughput in manufacturing facilities, along with the successful implementation of GPS, demonstrates a commitment to operational excellence. The company's focus on cash flow generation and working capital efficiency is expected to support deleveraging and enhance financial flexibility. Baxter's long-term earnings power is anticipated to be meaningfully better than current levels, driven by decisive steps in the early stages of its turnaround and a culture of continuous improvement.

Baxter's strategic focus on innovation and AI integration presents a significant growth opportunity. The company's recent launches, such as the IV Verified Line labeling system and the XR spine surgical table, demonstrate a commitment to targeted innovation. Additionally, the integration of AI into the Connected Care Foundation and frontline care products aims to accelerate future growth. These initiatives position Baxter to outgrow its markets and expand margins, leveraging its unique data set from IoT devices to provide actionable insights. The company's proactive approach to innovation, coupled with strong order growth for products like Dynamo, suggests a robust pipeline of differentiated solutions that could drive long-term shareholder value.
The company's efforts to stabilize the business and strengthen the balance sheet are showing early signs of success. Baxter's positive free cash flow generation in Q1 FY26 reflects progress in improving working capital efficiency. The company's target of net leverage of approximately 3x by the end of FY26 indicates a disciplined approach to debt reduction and financial flexibility. Once this leverage goal is achieved, Baxter will have more optionality for strategic tuck-in M&A and share repurchases, enhancing its growth profile and shareholder returns. The company's focus on continuous improvement through the Baxter Growth and Performance System (GPS) is expected to drive accountability and operational efficiency, further strengthening its financial position.
Baxter's exposure to macroeconomic risks, such as higher oil prices and conflict in the Middle East, is relatively low. With less than 2% of total revenue coming from the Middle East and significantly reduced exposure to fuel costs post-divestiture of the kidney business, Baxter is well-positioned to navigate broader economic uncertainties. The company's proactive supply chain management and dual sourcing efforts mitigate risks associated with inflation and supply chain disruptions. Baxter's ability to manage these risks while maintaining operational resilience underscores its potential for consistent performance and long-term growth.
The company's strategic priorities, including stabilizing the business, strengthening the balance sheet, and driving continuous improvement, are gaining traction. Baxter's progress in clearing back orders and increasing throughput in manufacturing facilities, along with the successful implementation of GPS, demonstrates a commitment to operational excellence. The company's focus on cash flow generation and working capital efficiency is expected to support deleveraging and enhance financial flexibility. Baxter's long-term earnings power is anticipated to be meaningfully better than current levels, driven by decisive steps in the early stages of its turnaround and a culture of continuous improvement.

▼ Bear case

Baxter faces significant headwinds from tariffs and higher manufacturing costs, which are expected to persist throughout FY26. The company's guidance assumes a full-year impact of approximately $80 million from tariffs, representing a year-over-year headwind of approximately $40 million. Higher manufacturing costs, including absorption pressure, are expected to be more pronounced in Q2 FY26. These cost pressures could negatively impact operating margins and earnings, posing a risk to Baxter's financial performance and ability to meet its guidance.
The potential impact of Novum LVP returns and exchanges remains a significant risk. Although Baxter did not see a material impact from customer returns in Q1 FY26, the company continues to factor this possibility into its full-year guidance. The ship and installation hold for Novum LVP is expected to remain in place for the full year, which could limit revenue growth and margin expansion. The uncertainty surrounding the resolution of the Novum shipment and installation hold, as well as the potential for customer returns, introduces downside risk to Baxter's financial outlook.
Baxter's Pharmaceutical segment continues to face supply constraints and softer market demand. The Injectables portfolio is negatively impacted by supply constraints and continued softness in certain products, while the Anesthesia portfolio reflects continued softer demand for inhaled anesthesia products globally. Although Baxter has made progress in clearing back orders at one of its manufacturing facilities, supply constraints associated with a contract manufacturer are expected to contribute to performance challenges into FY27. These pressures could limit the segment's ability to contribute to overall growth and profitability.
The company's reliance on the successful implementation of its turnaround strategy and GPS presents execution risks. While Baxter has made progress in delayering management teams and pushing down P&L responsibility to leaders of each operating business, the company is still in the early stages of organization-wide adoption. The success of GPS depends on the consistent application of rigorous KPI measures and the embedding of operating discipline into the company's culture. Failure to execute on these initiatives could hinder Baxter's ability to drive continuous improvement and achieve its long-term financial goals.
Baxter's exposure to macroeconomic risks, such as higher oil prices and broader inflationary pressures, could exacerbate existing challenges. Although the company's exposure to fuel costs has been reduced post-divestiture of the kidney business, higher oil prices and broader inflationary pressures could still impact Baxter's supply chain and manufacturing costs. The company's ability to mitigate these risks through proactive supply chain management and dual sourcing efforts will be critical to maintaining operational resilience and financial stability.

Baxter faces significant headwinds from tariffs and higher manufacturing costs, which are expected to persist throughout FY26. The company's guidance assumes a full-year impact of approximately $80 million from tariffs, representing a year-over-year headwind of approximately $40 million. Higher manufacturing costs, including absorption pressure, are expected to be more pronounced in Q2 FY26. These cost pressures could negatively impact operating margins and earnings, posing a risk to Baxter's financial performance and ability to meet its guidance.
The potential impact of Novum LVP returns and exchanges remains a significant risk. Although Baxter did not see a material impact from customer returns in Q1 FY26, the company continues to factor this possibility into its full-year guidance. The ship and installation hold for Novum LVP is expected to remain in place for the full year, which could limit revenue growth and margin expansion. The uncertainty surrounding the resolution of the Novum shipment and installation hold, as well as the potential for customer returns, introduces downside risk to Baxter's financial outlook.
Baxter's Pharmaceutical segment continues to face supply constraints and softer market demand. The Injectables portfolio is negatively impacted by supply constraints and continued softness in certain products, while the Anesthesia portfolio reflects continued softer demand for inhaled anesthesia products globally. Although Baxter has made progress in clearing back orders at one of its manufacturing facilities, supply constraints associated with a contract manufacturer are expected to contribute to performance challenges into FY27. These pressures could limit the segment's ability to contribute to overall growth and profitability.
The company's reliance on the successful implementation of its turnaround strategy and GPS presents execution risks. While Baxter has made progress in delayering management teams and pushing down P&L responsibility to leaders of each operating business, the company is still in the early stages of organization-wide adoption. The success of GPS depends on the consistent application of rigorous KPI measures and the embedding of operating discipline into the company's culture. Failure to execute on these initiatives could hinder Baxter's ability to drive continuous improvement and achieve its long-term financial goals.
Baxter's exposure to macroeconomic risks, such as higher oil prices and broader inflationary pressures, could exacerbate existing challenges. Although the company's exposure to fuel costs has been reduced post-divestiture of the kidney business, higher oil prices and broader inflationary pressures could still impact Baxter's supply chain and manufacturing costs. The company's ability to mitigate these risks through proactive supply chain management and dual sourcing efforts will be critical to maintaining operational resilience and financial stability.

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2023)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2023)

Peer Comparison

Create an account

Sign In

Reset Password